Investors & Media

Project Lightspeed Together with all companies, research institutes and governments global vaccine development capabilities. currently working on the development of a vaccine against COVID-19,

Aiming to address the global coronavirus pandemic:

19 vaccine to contribute to global efforts to combat the global COVID-19 pandemic and protect against COVID-19. Our effort to accelerate the rapid development of a vaccine to fight COVID-19 has been named "Project Lightspeed." The project leverages

we, at BioNTech, are also working around the clock to develop a COVID-

This website is intended for a global audience.


BioNTech's proprietary mRNA-based technology, with which we have more than 20 years of experience, and is also supported by Pfizer's

through stringent clinical testing and must be manufactured to high standards (termed "GMP" or good manufacturing practice) consistently

Careers Connect Healthcare Professionals

and reliably. BioNTech received German regulatory authority approval in 2011 to manufacture mRNA under GMP, and has been producing mRNA for clinical testing since then, including the entire clinical supply for our COVID-19 mRNA vaccine.

Like any other pharmaceutical product, a potential vaccine has to go



worldwide." Prof. Ugur Sahin, M.D., Chief Executive Officer

immunotherapy expertise to help address the COVID-19

vaccine available to the public as quickly as possible -

pandemic emergency. Our aim is clear: Making a potential

"We feel a duty to exploit our full technology and



August 5, 2020: Start of the clinical study in China and supply agreement with Canada August 20, 2020:

Preliminary data from ongoing Phase 1/2 study of lead COVID-19 mRNA vaccine

candidate

October 6-9, 2020:

November 11, 2020:

November 18, 2020:

November 25, 2020:

December 2, 2020:

December 21, 2020:

COVID-19 mRNA vaccine

Rolling submissions initiated

Acquisition of GMP manufacturing site

Vaccine Supply Agreement with the EU

Conclusion of global Phase 3 study

September 7, 2020: Start of Phase 2/3 study in Germany September 17, 2020:

November 9, 2020: Preliminary data: first positive interim analysis from global phase 3 study

November 16, 2020: **Approval of Phase 2 study in China**

November 20, 2020: **Emergency Use Authorization Request submitted to U.S. FDA**

Start of clinical Phase 2 study in China November 30, 2020: **Conditional Marketing Authorization Submission to EMA**

December 11, 2020: U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use


First approval of a temporary emergency supply in UK

Conditional Marketing Authorization in the European Union for BioNTech's

For more information about our manufacturing capabilities please visit: • https://biontech.de/how-we-translate/manufacturing

For more information on the current status of the vaccine program please follow: Press releases

Read also



> Imprint

> Adverse Event Reporting

Cookie Settings

We look forward to connecting with you

> Connect

> Our DNA

Follow us

SEND US A MESSAGE



infectious diseases

BIONTECH

BioNTech Manufacturing GmbH

> How We Translate Science > For Patients >Investors & Media **>** Careers

in 🗆 > Terms Of Use > General Terms And Conditions General Conditions Of Purchase > Data Privacy Statement > Data Processing Terms Business Partners